A prospective open-label study to determine effectiveness of Erenumab in treating headaches in idiopathic intracranial hypertension in ocular remission (resolved papilledema)
Latest Information Update: 23 Dec 2020
At a glance
- Drugs Erenumab (Primary)
- Indications Headache; Migraine
- Focus Therapeutic Use
- 23 Dec 2020 New trial record
- 14 Dec 2020 Primary endpoint (Change in monthly moderate/severe headache days (MmsHD) from baseline (30day pretreatment period) compared to 12 months.) has been met, according to results published in the Headache
- 14 Dec 2020 Results of primary analysis of the data published in the Headache